CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant advancements ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

Illumina Inc (ILMN) reports steady revenue growth and strategic advancements, while addressing competitive pressures and geopolitical risks.

The company launched several new products, including the NovaSeq X series. Illumina is focusing on expansion in multiomics and data services. Illumina's performance in Q4 2024 showed modest growth ...

Investing.com -- TD Cowen downgraded Illumina Inc (NASDAQ ... with weaker NovaSeq pull-through offsetting stronger instrument sales. The firm also noted concerns over the long-term acceleration of the ...

The Illumina MiSeq i100 Series ... the company calls "universal software"-meaning that the MiSeq i100 and NovaSeq X leverage many of the same software components, even though the instruments ...